- Reuters•2 hours ago
AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.
- The Wall Street Journal•2 hours ago
U.K. drug maker AstraZeneca, battling declining sales of its blockbuster cholesterol pill, posted lower revenue and profit in the first quarter of the year.
- Investor's Business Daily•3 hours ago
The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,653.00 x 6100|
|Ask||4,653.50 x 13000|
|Day's Range||4,604.00 - 4,775.56|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||16.86|
|Dividend & Yield||2.80 (4.81%)|
|1y Target Est||N/A|